Oncobiologics Warrants Series A Exp 18 Feb 2019 (ONSIW) SWOT Analysis / TOWS Matrix / MBA Resources
Strategy / MBA Resources
Introduction to SWOT Analysis
SWOT Analysis / TOWS Matrix for Oncobiologics Warrants Series A Exp 18 Feb 2019 (United States)
Based on various researches at Oak Spring University , Oncobiologics Warrants Series A Exp 18 Feb 2019 is operating in a macro-environment that has been destablized by – talent flight as more people leaving formal jobs, challanges to central banks by blockchain based private currencies, increasing commodity prices, customer relationship management is fast transforming because of increasing concerns over data privacy, wage bills are increasing, there is increasing trade war between United States & China, increasing energy prices,
banking and financial system is disrupted by Bitcoin and other crypto currencies, supply chains are disrupted by pandemic , etc
Introduction to SWOT Analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University, we believe that Oncobiologics Warrants Series A Exp 18 Feb 2019 can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Oncobiologics Warrants Series A Exp 18 Feb 2019, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Oncobiologics Warrants Series A Exp 18 Feb 2019 operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 can be done for the following purposes –
1. Strategic planning of Oncobiologics Warrants Series A Exp 18 Feb 2019
2. Improving business portfolio management of Oncobiologics Warrants Series A Exp 18 Feb 2019
3. Assessing feasibility of the new initiative in United States
4. Making a sector specific business decision
5. Set goals for the organization
6. Organizational restructuring of Oncobiologics Warrants Series A Exp 18 Feb 2019
Strengths of Oncobiologics Warrants Series A Exp 18 Feb 2019 | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Low bargaining power of suppliers
– Suppliers of Oncobiologics Warrants Series A Exp 18 Feb 2019 in the sector have low bargaining power. Oncobiologics Warrants Series A Exp 18 Feb 2019 has further diversified its suppliers portfolio by building a robust supply chain across various countries. This helps Oncobiologics Warrants Series A Exp 18 Feb 2019 to manage not only supply disruptions but also source products at highly competitive prices.
Strong track record of project management in the industry
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is known for sticking to its project targets. This enables the firm to manage – time, project costs, and have sustainable margins on the projects.
Highly skilled collaborators
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has highly efficient outsourcing and offshoring strategy. It has resulted in greater operational flexibility and bringing down the costs in highly price sensitive industry. Secondly the value chain collaborators of Oncobiologics Warrants Series A Exp 18 Feb 2019 have helped the firm to develop new products and bring them quickly to the marketplace.
Successful track record of launching new products
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has launched numerous new products in last few years, keeping in mind evolving customer preferences and competitive pressures. Oncobiologics Warrants Series A Exp 18 Feb 2019 has effective processes in place that helps in exploring new product needs, doing quick pilot testing, and then launching the products quickly using its extensive distribution network.
Ability to recruit top talent
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is one of the leading players in the industry in United States. It is in a position to attract the best talent available in United States. The firm has a robust talent identification program that helps in identifying the brightest.
Learning organization
- Oncobiologics Warrants Series A Exp 18 Feb 2019 is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Oncobiologics Warrants Series A Exp 18 Feb 2019 is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders at Oncobiologics Warrants Series A Exp 18 Feb 2019 emphasize – knowledge, initiative, and innovation.
Sustainable margins compare to other players in industry
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has clearly differentiated products in the market place. This has enabled Oncobiologics Warrants Series A Exp 18 Feb 2019 to fetch slight price premium compare to the competitors in the industry. The sustainable margins have also helped Oncobiologics Warrants Series A Exp 18 Feb 2019 to invest into research and development (R&D) and innovation.
Organizational Resilience of Oncobiologics Warrants Series A Exp 18 Feb 2019
– The covid-19 pandemic has put organizational resilience at the centre of everthing Oncobiologics Warrants Series A Exp 18 Feb 2019 does. Organizational resilience comprises - Financial Resilience, Operational Resilience, Technological Resilience, Organizational Resilience, Business Model Resilience, and Reputation Resilience.
Ability to lead change in
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is one of the leading players in the industry in United States. Over the years it has not only transformed the business landscape in the industry in United States but also across the existing markets. The ability to lead change has enabled Oncobiologics Warrants Series A Exp 18 Feb 2019 in – penetrating new markets, reaching out to new customers, and providing different value propositions to different customers in the international markets.
Superior customer experience
– The customer experience strategy of Oncobiologics Warrants Series A Exp 18 Feb 2019 in industry is based on four key concepts – personalization, simplification of complex needs, prompt response, and continuous engagement.
High brand equity
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has strong brand awareness and brand recognition among both - the exiting customers and potential new customers. Strong brand equity has enabled Oncobiologics Warrants Series A Exp 18 Feb 2019 to keep acquiring new customers and building profitable relationship with both the new and loyal customers.
Innovation driven organization
– Oncobiologics Warrants Series A Exp 18 Feb 2019 is one of the most innovative firm in sector.
Weaknesses of Oncobiologics Warrants Series A Exp 18 Feb 2019 | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Ability to respond to the competition
– As the decision making is very deliberative at Oncobiologics Warrants Series A Exp 18 Feb 2019, in the dynamic environment of industry it has struggled to respond to the nimble upstart competition. Oncobiologics Warrants Series A Exp 18 Feb 2019 has reasonably good record with similar level competitors but it has struggled with new entrants taking away niches of its business.
Products dominated business model
– Even though Oncobiologics Warrants Series A Exp 18 Feb 2019 has some of the most successful models in the industry, this business model has made each new product launch extremely critical for continuous financial growth of the organization. Oncobiologics Warrants Series A Exp 18 Feb 2019 should strive to include more intangible value offerings along with its core products and services.
No frontier risks strategy
– From the 10K / annual statement of Oncobiologics Warrants Series A Exp 18 Feb 2019, it seems that company is thinking out the frontier risks that can impact industry. But it has very little resources allocation to manage the risks emerging from events such as natural disasters, climate change, melting of permafrost, tacking the rise of artificial intelligence, opportunities and threats emerging from commercialization of space etc.
Workers concerns about automation
– As automation is fast increasing in the industry, Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to come up with a strategy to reduce the workers concern regarding automation. Without a clear strategy, it could lead to disruption and uncertainty within the organization.
Skills based hiring in industry
– The stress on hiring functional specialists at Oncobiologics Warrants Series A Exp 18 Feb 2019 has created an environment where the organization is dominated by functional specialists rather than management generalist. This has resulted into product oriented approach rather than marketing oriented approach or consumers oriented approach.
Low market penetration in new markets
– Outside its home market of United States, Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to spend more promotional, marketing, and advertising efforts to penetrate international markets.
Aligning sales with marketing
– From the outside it seems that Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to have more collaboration between its sales team and marketing team. Sales professionals in the industry have deep experience in developing customer relationships. Marketing department at Oncobiologics Warrants Series A Exp 18 Feb 2019 can leverage the sales team experience to cultivate customer relationships as Oncobiologics Warrants Series A Exp 18 Feb 2019 is planning to shift buying processes online.
High dependence on existing supply chain
– The disruption in the global supply chains because of the Covid-19 pandemic and blockage of the Suez Canal illustrated the fragile nature of Oncobiologics Warrants Series A Exp 18 Feb 2019 supply chain. Even after few cautionary changes, Oncobiologics Warrants Series A Exp 18 Feb 2019 is still heavily dependent upon the existing supply chain. The existing supply chain though brings in cost efficiencies but it has left Oncobiologics Warrants Series A Exp 18 Feb 2019 vulnerable to further global disruptions in South East Asia.
Slow decision making process
– As mentioned earlier in the report, Oncobiologics Warrants Series A Exp 18 Feb 2019 has a very deliberative decision making approach. This approach has resulted in prudent decisions, but it has also resulted in missing opportunities in the industry over the last five years. Oncobiologics Warrants Series A Exp 18 Feb 2019 even though has strong showing on digital transformation primary two stages, it has struggled to capitalize the power of digital transformation in marketing efforts and new venture efforts.
Lack of clear differentiation of Oncobiologics Warrants Series A Exp 18 Feb 2019 products
– To increase the profitability and margins on the products, Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to provide more differentiated products than what it is currently offering in the marketplace.
Interest costs
– Compare to the competition, Oncobiologics Warrants Series A Exp 18 Feb 2019 has borrowed money from the capital market at higher rates. It needs to restructure the interest payment and costs so that it can compete better and improve profitability.
Oncobiologics Warrants Series A Exp 18 Feb 2019 Opportunities | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Reconfiguring business model
– The expansion of digital payment system, the bringing down of international transactions costs using Bitcoin and other blockchain based currencies, etc can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to reconfigure its entire business model. For example it can used blockchain based technologies to reduce piracy of its products in the big markets such as China. Secondly it can use the popularity of e-commerce in various developing markets to build a Direct to Customer business model rather than the current Channel Heavy distribution network.
Learning at scale
– Online learning technologies has now opened space for Oncobiologics Warrants Series A Exp 18 Feb 2019 to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Lowering marketing communication costs
– 5G expansion will open new opportunities for Oncobiologics Warrants Series A Exp 18 Feb 2019 in the field of marketing communication. It will bring down the cost of doing business, provide technology platform to build new products in the industry, and it will provide faster access to the consumers.
Increase in government spending
– As the United States and other governments are increasing social spending and infrastructure spending to build economies post Covid-19, Oncobiologics Warrants Series A Exp 18 Feb 2019 can use these opportunities to build new business models that can help the communities that Oncobiologics Warrants Series A Exp 18 Feb 2019 operates in. Secondly it can use opportunities from government spending in sector.
Identify volunteer opportunities
– Covid-19 has impacted working population in two ways – it has led to people soul searching about their professional choices, resulting in mass resignation. Secondly it has encouraged people to do things that they are passionate about. This has opened opportunities for businesses to build volunteer oriented socially driven projects. Oncobiologics Warrants Series A Exp 18 Feb 2019 can explore opportunities that can attract volunteers and are consistent with its mission and vision.
Manufacturing automation
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can use the latest technology developments to improve its manufacturing and designing process in sector. It can use CAD and 3D printing to build a quick prototype and pilot testing products. It can leverage automation using machine learning and artificial intelligence to do faster production at lowers costs, and it can leverage the growth in satellite and tracking technologies to improve inventory management, transportation, and shipping.
Use of Bitcoin and other crypto currencies for transactions in industry
– The popularity of Bitcoin and other crypto currencies as asset class and medium of transaction has opened new opportunities for Oncobiologics Warrants Series A Exp 18 Feb 2019 in the industry. Now Oncobiologics Warrants Series A Exp 18 Feb 2019 can target international markets with far fewer capital restrictions requirements than the existing system.
Leveraging digital technologies
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can leverage digital technologies such as artificial intelligence and machine learning to automate the production process, customer analytics to get better insights into consumer behavior, realtime digital dashboards to get better sales tracking, logistics and transportation, product tracking, etc.
Low interest rates
– Even though inflation is raising its head in most developed economies, Oncobiologics Warrants Series A Exp 18 Feb 2019 can still utilize the low interest rates to borrow money for capital investment. Secondly it can also use the increase of government spending in infrastructure projects to get new business.
Better consumer reach
– The expansion of the 5G network will help Oncobiologics Warrants Series A Exp 18 Feb 2019 to increase its market reach. Oncobiologics Warrants Series A Exp 18 Feb 2019 will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Creating value in data economy
– The success of analytics program of Oncobiologics Warrants Series A Exp 18 Feb 2019 has opened avenues for new revenue streams for the organization in industry. This can help Oncobiologics Warrants Series A Exp 18 Feb 2019 to build a more holistic ecosystem for Oncobiologics Warrants Series A Exp 18 Feb 2019 products in the industry by providing – data insight services, data privacy related products, data based consulting services, etc.
Buying journey improvements
– Oncobiologics Warrants Series A Exp 18 Feb 2019 can improve the customer journey of consumers in the industry by using analytics and artificial intelligence. It can provide automated chats to help consumers solve their own problems, provide online suggestions to get maximum out of the products and services, and help consumers to build a community where they can interact with each other to develop new features and uses.
Finding new ways to collaborate
– Covid-19 has not only transformed business models of companies in industry, but it has also influenced the consumer preferences. Oncobiologics Warrants Series A Exp 18 Feb 2019 can tie-up with other value chain partners to explore new opportunities regarding meeting customer demands and building a rewarding and engaging relationship.
Threats Oncobiologics Warrants Series A Exp 18 Feb 2019 External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats of Oncobiologics Warrants Series A Exp 18 Feb 2019 are -
Shortening product life cycle
– it is one of the major threat that Oncobiologics Warrants Series A Exp 18 Feb 2019 is facing in sector. It can lead to higher research and development costs, higher marketing expenses, lower customer loyalty, etc.
Consumer confidence and its impact on Oncobiologics Warrants Series A Exp 18 Feb 2019 demand
– There is a high probability of declining consumer confidence, given – high inflammation rate, rise of gig economy, lower job stability, increasing cost of living, higher interest rates, and aging demography. All the factors contribute to people saving higher rate of their income, resulting in lower consumer demand in industry and other sectors.
Instability in the European markets
– European Union markets are facing three big challenges post Covid – expanded balance sheets, Brexit related business disruption, and aggressive Russia looking to distract the existing security mechanism. Oncobiologics Warrants Series A Exp 18 Feb 2019 will face different problems in different parts of Europe. For example it will face inflationary pressures in UK, France, and Germany, balance sheet expansion and demand challenges in Southern European countries, and geopolitical instability in the Eastern Europe.
Increasing international competition and downward pressure on margins
– Apart from technology driven competitive advantage dilution, Oncobiologics Warrants Series A Exp 18 Feb 2019 can face downward pressure on margins from increasing competition from international players. The international players have stable revenue in their home market and can use those resources to penetrate Oncobiologics Warrants Series A Exp 18 Feb 2019 prominent markets.
Capital market disruption
– During the Covid-19, Dow Jones has touched record high. The valuations of a number of companies are way beyond their existing business model potential. This can lead to capital market correction which can put a number of suppliers, collaborators, value chain partners in great financial difficulty. It will directly impact the business of Oncobiologics Warrants Series A Exp 18 Feb 2019.
New competition
– After the dotcom bust of 2001, financial crisis of 2008-09, the business formation in US economy had declined. But in 2020 alone, there are more than 1.5 million new business applications in United States. This can lead to greater competition for Oncobiologics Warrants Series A Exp 18 Feb 2019 in the sector and impact the bottomline of the organization.
Barriers of entry lowering
– As technology is more democratized, the barriers to entry to industry are lowering. It can presents Oncobiologics Warrants Series A Exp 18 Feb 2019 with greater competitive threats in the near to medium future. Secondly it will also put downward pressure on pricing throughout the sector.
High level of anxiety and lack of motivation
– the Great Resignation in United States is the sign of broader dissatisfaction among the workforce in United States. Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to understand the core reasons impacting the industry. This will help it in building a better workplace.
Technology acceleration in Forth Industrial Revolution
– Oncobiologics Warrants Series A Exp 18 Feb 2019 has witnessed rapid integration of technology during Covid-19 in the industry. As one of the leading players in the industry, Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to keep up with the evolution of technology in the sector. According to Mckinsey study top managers believe that the adoption of technology in operations, communications is 20-25 times faster than what they planned in the beginning of 2019.
Aging population
– As the populations of most advanced economies are aging, it will lead to high social security costs, higher savings among population, and lower demand for goods and services in the economy. The household savings in US, France, UK, Germany, and Japan are growing faster than predicted because of uncertainty caused by pandemic.
Learning curve for new practices
– As the technology based on artificial intelligence and machine learning platform is getting complex, Oncobiologics Warrants Series A Exp 18 Feb 2019 may face longer learning curve for training and development of existing employees. This can open space for more nimble competitors in the field of sector.
Environmental challenges
– Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to have a robust strategy against the disruptions arising from climate change and energy requirements. EU has identified it as key priority area and spending 30% of its 880 billion Euros European post Covid-19 recovery funds on green technology. Oncobiologics Warrants Series A Exp 18 Feb 2019 can take advantage of this fund but it will also bring new competitors in the industry.
Technology disruption because of hacks, piracy etc
– The colonial pipeline illustrated, how vulnerable modern organization are to international hackers, miscreants, and disruptors. The cyber security interruption, data leaks, etc can seriously jeopardize the future growth of the organization.
Weighted SWOT Analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers at Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Oncobiologics Warrants Series A Exp 18 Feb 2019 to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Oncobiologics Warrants Series A Exp 18 Feb 2019 needs to make to build a sustainable competitive advantage.
